Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy

Tingting Feng1,2, Wei Cao3, Wanxiang Shen4

  • 1Laboratory of Molecular Target Therapy of Cancer, Institute of Basic Medical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000, China.

Oncotarget
|November 19, 2016
PubMed

Insights

Arctigenin effectively inhibits triple-negative breast cancer (TNBC) by targeting STAT3, reducing cell growth and promoting apoptosis. This natural compound also enhances chemotherapy, showing promise as a novel TNBC therapeutic agent.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options.
  • Arctigenin (Atn), a natural lignan, exhibits anticancer properties, but its efficacy against TNBC is not well understood.
  • STAT3 signaling is frequently dysregulated in TNBC, contributing to tumor progression and resistance.

Purpose of the Study:

  • To investigate the therapeutic potential of Arctigenin (Atn) against triple-negative breast cancer (TNBC).
  • To elucidate the molecular mechanism underlying Atn's anti-TNBC effects, focusing on STAT3.
  • To evaluate Atn's efficacy as a combination therapy with Taxotere® and its in vivo antitumor activity.

Main Methods:

  • In vitro studies assessing TNBC cell proliferation and apoptosis induction by Atn.
  • Computational docking and affinity assays to identify Atn's molecular target.
  • Analysis of Atn's effect on STAT3-DNA binding and STAT3 signaling pathway.
  • In vivo xenograft models to evaluate Atn's antitumor efficacy and combination therapy with Taxotere®.

Main Results:

  • Arctigenin significantly decreased proliferation and induced apoptosis in TNBC cells.
  • Atn was found to bind to the SH2 domain of STAT3, inhibiting its binding to genomic DNA.
  • Atn enhanced the cytotoxic effects of Taxotere® on TNBC cells.
  • In vivo studies confirmed the antitumor activity of Atn in TNBC xenografts.

Conclusions:

  • Arctigenin demonstrates significant anti-TNBC activity by inhibiting STAT3 signaling.
  • Atn shows potential as a standalone therapeutic agent and in combination with chemotherapy for TNBC.
  • Atn represents a promising candidate for developing novel STAT3 inhibitors for TNBC treatment.
Keywords:
STAT3arctigenincomputational dockingtaxoteretriple-negative breast cancers

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.8K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K